Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Florida College of Medicine, Gainesville, Florida, USA.
Curr Opin Pediatr. 2023 Oct 1;35(5):574-578. doi: 10.1097/MOP.0000000000001280. Epub 2023 Aug 4.
This review aims to summarize the most up-to-date criteria for diagnosis of pediatric irritable bowel syndrome (IBS) and treatment options. It also explores recent research that has been performed evaluating risk factors, pathophysiology, and treatment designed to improve quality of life for those who suffer from IBS. IBS is a common disorder in pediatrics and one of the most common causes of abdominal pain for children; thus, it can be quite debilitating for individuals to achieve a satisfactory quality of life on a routine basis. Reliable, available treatment is needed but can be challenging to find, given the variety of symptoms and triggers involved and lack of a clear understanding of how IBS develops.
There are multiple pharmacologic and nonpharmacologic treatment options being explored and studied globally but further, larger, and well controlled studies are needed to confirm these outcomes.
Because pediatric IBS is one of the most common functional disorders associated with abdominal pain and can be brought on by multiple factors, management often involves addressing these individual triggers with a multifaceted treatment plan, which could include dietary changes, probiotics, medication, or psychotherapy and should be tailored to each affected individual.
本文旨在总结最新的儿科肠易激综合征(IBS)诊断标准和治疗选择。同时探讨最近的研究进展,评估风险因素、病理生理学以及旨在改善 IBS 患者生活质量的治疗方法。IBS 在儿科中较为常见,是儿童腹痛的最常见原因之一,因此,对于个人而言,在日常生活中获得满意的生活质量可能非常困难。由于涉及多种症状和诱因,并且对 IBS 的发展机制缺乏清晰的了解,因此需要可靠、可用的治疗方法,但这可能具有挑战性。
目前正在探索和研究多种药物和非药物治疗选择,但需要进行更多、更大规模和对照良好的研究来证实这些结果。
由于儿科 IBS 是最常见的与腹痛相关的功能性疾病之一,并且可能由多种因素引起,因此管理通常涉及针对这些个体触发因素的多方面治疗计划,其中可能包括饮食改变、益生菌、药物或心理治疗,并且应根据每个受影响的个体进行调整。